Kornimate/medical-research-clean huggingface dataset:
multicenter clinical trial for adult ph-negative all. non-intensive but non-iterruptive treatment

Conditions: Ph-negative Adult Acute Lymphoblastic Leukemia

Summary: 1. evaluation of blast clearance in b/m after 7 days of prednisolone prephase and the efficacy of its substitution by dexamethasone if blast count is 25% and more 2. feasibility for adults of "no interruptions" protocol with 8 weeks induction and 14 weeks consolidation followed by 2-years maintenance. 3. tolerability and efficacy in adults of the prolonged l-asparaginase application (total proposed dose 560.000 iu) 4. feasibility and efficacy of autologous stem cell transplantation for t-cell all

1. the blast count in b/m after 7 days of prednisolone \>25% was shown in 64% of patients. the substitution of prednisolone by dexamethasone did not influence survival. 2. "no interruptions" induction was performed in 48% of patients. 3. in 19% of patients the l-asparaginase therapy was stopped due to toxicity. 4. autologous stem cell transplantation was done in 20% of t-cell all patients.

Eligibility criteria:
inclusion criteria: * ph-negative precursors all * age 15-55 years * nontreated * eastern cooperative oncology group criterion status 0-3 exclusion criteria: * b-mature all * ph-positivity * pretreatment * eastern cooperative oncology group criterion status 4

Keywords: adult all ph-negative dexamethasone l-asparaginase
effect of increased positive end-expiratory pressure on intracranial pressure in different respiratory mechanic in acute respiratory distress syndrome

Conditions: Acute Brain Injuries

Summary: there are concerns that the use of positive end-expiratory pressure (peep) for the treatment of pulmonary complications in patients with brain injury may potentially elevate intracranial pressure (icp), and deteriorate neurological status. it is suggested that both respiratory system compliance and ventricular compliance would contribute to the elevation of icp when peep increases. in theory, peep may cause elevation of icp by increasing intrathoracic pressure and diminish venous return. however, the transmission of peep into thoracic cavity depends on the properties of the lung and chest wall. experimental study showed that when chest wall compliance is low, peep can significantly increases intrathoracic pressure; whereas low lung compliance can minimize airway pressure transmission. it is generally recognized that the lung compliance decreases in acute respiratory distress syndrome (ards) patients due to extensive alveolar collapse. however, it has been report that the elastance ratio (the ratio between elastance of the chest wall and the respiratory system, where elastance is the reciprocal of compliance) may vary from 0.2 to 0.8. therefore, it is important to distinguish the compliance of the chest wall and the lung when investigating the effect of peep on icp. because intrathoracic pressure (pleural pressure) is difficult to measure in clinical situations, esophageal pressure (pes) is considered as a surrogate of intrathoracic pressure. in the present study, the investigators determine the effect of peep on intrathoracic pressure and icp by pes measurement.


Eligibility criteria:
inclusion criteria: 1. age 18 years and above; 2. glasgow coma score ≤ 8; 3. ventricular icp monitor was placed for icp monitoring and cerebrospinal fluid (csf) drainage; 4. need for mechanical ventilation with peep; 5. ards was diagnosed according to berlin definition. exclusion criteria: 1. hemodynamic instability requiring more than 10 μg/kg/min dopamine or more than 0.5 μg/kg/min norepinephrine; 2. icp \> 25 mmhg; 3. esophageal varices; 4. history of esophageal or gastric surgery; 5. evidence of active air leak from the lung, including bronchopleural fistula, pneumothorax, pneumomediastinum, or existing chest tube; 6. history of chronic obstructive pulmonary disease.

Keywords: mechanical ventilation positive end-expiratory pressure
efficacy and safety of sp2086 as monotherapy in patients with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: sp2086 is a new dipeptidy1 peptidase(dpp)-4 inhibitors. this study aims to evaluate the efficacy and safety of sp2086 as monotherapy in patients with type 2 diabetes mellitus in metformin monotherapy who have inadequate glycemic control treated with diet and exercise for 3 months


Eligibility criteria:
inclusion criteria: * patients diagnosed with type 2 diabetes mellitus * patients have treated with diet/exercise at least 3 months * 7.5% ≤hba1c ≤11.0% at screening,7.0% ≤hba1c ≤10.5% after run-in exclusion criteria: * patient has history of type 1 diabetes mellitus * patient has history of ketoacidosis * patient has history of severe unconscious hypoglycemosis * patient has history of acute and chronic pancreatitis or pancreatic injury that may lead to high risk of pancreatitis * patient has history of decompensated heart failure (nyha class iii and iv), unstable angina, stroke or transient ischemic attack, myocardial infarction, persistence and clinical * patient has history of a history of hypertension, and after antihypertensive treatment, systolic blood pressure ≥ 160 mmhg or diastolic blood pressure ≥ 100 mmhg * patient has severe liver or kidney disease,alanine aminotransferase \>2×unl, aspartate aminotransferase \>2×upper normal limit(unl)；total bilirubin \>2×unl； creatinine\>1.5 mg/dl (male,132.6μmol/l) ，\>1.4 mg/dl(female，123.8μmol/l) * patient has severe chronic gastrointestinal disease or therapy that may affect drug absorption, such as gastrointestinal surgery * patient has severe haematological diseases or other diseases leading to hemolyze and red blood cell unstable (malaria、haemolytic anaemia eg. ) * patient has other endocrine diseases, for example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on * patient has history of malignancy * patient has history of alcohol or drug abuse

Keywords: sp2086 phase iii monotherapy
comparison of occlusive and classical hypertrophy training in terms of thickness and stiffness of the muscle

Conditions: Muscle Tightness; Hypertrophy; Occlusion Vein

Summary: occlusive or ischemic training is a type of strength training which is becoming more and more popular every day. the safety, efficacy and detailed description about the use of occlusive training is well documented in the literature. however, the effects on hypertrophy and the stiffness of the muscle tissue are not studied. we aimed to measure these changes by ultrasound technology in a randomized controlled design.

patients were randomized into classical hypertrophy and occlusive hypertrophy groups. the participants are free from any systemic disease, infection or recent injury. both groups perform hypertrophy training with different intensities. the outcome measures are; thickness determined by b-mode ultrasound and stiffness by shear-wave elastography. comparison of both groups will be made.

Eligibility criteria:
inclusion criteria: * healthy recreational athletes exclusion criteria: * any kind of systemic disorder * active or chronic infection * recent (last 6 months) musculoskeletal injury * performed strength training at last 72 hours

Keywords: biomechanics strength training elastography ultrasound
emulation of randomized clinical trial in cardiovascular disease

Conditions: Myocardial Infarction; Coronary Artery Disease

Summary: investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. the investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

this is a non-randomized, non-interventional study from korean national health insurance service database. although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice.

Eligibility criteria:
inclusion criteria: * - pci with mi (i21) admission * age more than 40 or less than 80 years old * aspirin and clopidogrel/prasugrel/ticagrelor prescription with more than 2 days at discharge exclusion criteria: * - previous use of a ppi, an h2-receptor antagonist, sucralfate, or misoprostol within 30 days before admission * preexisting cancer within a year before admission * history of rbc transfusion * rbc transfusion in admission * cardiogenic shock * length of stay more than 14 days * oac prescription with more than 2 days at discharge * h2 prescription with more than 2 days at discharge

Keywords: percutaneous coronary intervention cardiovascular pharmacotherapy proton pump inhibitor dual antiplatelet therapy
covid-19 in pain perspective

Conditions: Infection; COVID; Pain

Summary: in our hospital's infectious diseases and clinical microbiology service, patients who have been hospitalized due to covid -19 infection have a musculoskeletal pain and headache during this process, and 466 patients will be recruited to compare them with the pre-disease state of the patients and to evaluate the pain status of the patients after treatment.

this retrospectively designed study was carried out by analyzing sars-cov-2 infected and hospitalized patients in our hospital for 2 month. the patients, whose contact information can be accessed from the hospital records, will be called by phone and pain inquiries were made during the sars-cov-2 infection process. in addition, patients' demographic data, living conditions (number and characteristics of the person in the household), comorbidities, symptom inquiry related to infection, duration of symptoms, length of hospitalstay, pre-infection pain conditions and current pain, anxiety, depression levels and quality of life will be questioned. the pain questioning include the painful body region/s, severity (numeric rating scale), type of analgesic drugs used, and duration of use that occurred during infection. anxiety and depression levels will be evaluated, hospital anxiety and depression scale (hads), and quality of life will be evaluated with sf-12 health assessment questionnaire.

Eligibility criteria:
inclusion criteria: * patients with positive pcr test results obtained from combined throat and nasopharyngeal swab samples * patients consistent with covid-19 infection as a result of thorax computed tomography, although pcr test results were negative. exclusion criteria: * patients who have undergone surgery and trauma in the painful area in the past 3 months, * patients with pathological disease that can cause underlying pain * pregnant women * those who have psychiatric illness and use psychiatric drugs * presence of malignancy * patients with severe cognitive deficits

Keywords: infections pain coronavirus
circulating prcp in stemi patients undergoing primary pci

Conditions: Myocardial Infarction; Percutaneous Coronary Intervention; PRCP

Summary: purpose: the purpose of this study is to evaluate the impact of acute st-segment elevation myocardial infarction (stemi) and primary percutaneous coronary intervention (pci) on circulating prolylcarboxypeptidase (prcp) level and activity.


Eligibility criteria:
inclusion criteria: * admitted for primary pci for stemi involving the lad within 12 hours of onset of symptoms. stemi will be defined as typical ecg changes (st segment elevation ≥2mm in 2 or more precordial leads) associated with acute chest pain or an elevation of cardiac enzymes; * age ≥18 years; * informed consent from subject or next of kin. exclusion criteria: * nonischaemic cardiomyopathy; * cardiac surgery planed in the 6 months; * mechanical complication of stemi (ventricular septal rupture, free wall rupture, acute severe mitral regurgitation); * renal or hepatic failure; * malignancy, hiv, or central nervous system disorder; * cardiopulmonary resuscitation \>15 min and compromised level of consciousness; * cardiogenic shock; * current participation in any research study involving investigational drugs or devices; * no written consensus; * previous myocardial infarction.
engagement to care south africa

Conditions: HIV

Summary: this study will evaluate the efficacy of two strategies for enhancing overall preventive behaviors, retention in hiv care, and adherence to medication for hiv positive individuals in south africa: short message service (sms) text messaging and peer navigation services.

treatment-as-prevention represents a game changing potential to stem further hiv transmission by ensuring that infected individuals are tested, linked to care, retained in care, and adherent to their regimens. little is known, however, about the most feasible and cost-effective means to promote overall engagement in care coupled with behavioral risk reduction for hiv positive individuals in south africa. for this reason, the study proposes to first assess what engagement in care activities are underway in select clinics in the bojanala platinum district, north west province, south africa, and will then implement and evaluate the feasibility, acceptability, and potential efficacy of two strategies for enhancing overall preventive behaviors, retention in hiv care and adherence to medication. the first strategy will employ automated text message reminders to encourage patients to return for needed care, adhere to their antiretroviral therapy (art) regimens, and practice safer sex and other risk reduction behaviors. this approach also includes designation of a retention, adherence, and prevention monitor to supervise the system. a second strategy builds on the first model, including the automated text message system, but also utilizes peer navigator-provider teams to serve as point people for care engagement. peer navigators will work with providers to introduce patients to care and help them establish a care and prevention plan. they will also check in with patients to discuss and support resolution of challenges to engaging in care, adhering to drug regimens, and reducing transmission risk behavior.

Eligibility criteria:
inclusion criteria: * hiv positive (diagnosed within the last 12 months prior to study/patient contact) * has access to a mobile phone * willing to receive and respond to text messages and calls from clinic and study staff (all arms) * willing to communicate and meet with pn (pn arm) * willing to meet with study staff for survey at study start, 6 months, and 12 months (all arms) * regard study clinic area as the regular clinic for accessing healthcare exclusion criteria: * first tested positive over 12 months prior to recruitment * under the age of 18 * unable to give informed consent * unable to read basic english and with no one to read study sms to participant * principally accesses care through a clinic not in the study * planning to permanently move away from the area served by the clinic within next 6 months (following enrollment)

Keywords: hiv-positive adherence engagement to care mobile health (mhealth) sms peer navigation retention
reducing risk of type 2 diabetes: hydroxychloroquine use in pre-diabetes

Conditions: Pre-diabetes

Summary: the purpose of this study is to determine the short-term effects of the antimalarial medication, hydroxychloroquine (hcq), compared with placebo using frequently sampled intravenous glucose tolerance testing (fsigtt) methodology to study changes in insulin secretion and glucose tolerance in subjects at risk for developing type 2 diabetes.

diabetes is approaching epidemic proportions in the united states. this study evaluates the mechanisms of action of a generic drug that may have effects on glucose metabolism.

Eligibility criteria:
inclusion criteria: 1. age \> or = 18, able to provide informed consent 2. body-mass index greater than or equal to 25 3. presence of at least one indicator of insulin resistance from the following list: * family history of type 2 diabetes (parent, sibling) * fasting glucose 100 - 125 mg/dl * fasting serum insulin greater than or equal to 7uu/ml * personal history of gestational diabetes 4. negative pregnancy test for women with childbearing potential exclusion criteria: 1. diagnosis of diabetes mellitus type 1 or type 2 2. active autoimmune disease, chronic infection, current malignancy (excluding basal cell carcinoma), or other active inflammatory state that, in the opinion of the investigators, would affect insulin sensitivity 3. oral corticosteroid use in prior six months, or expectation of needing corticosteroid therapy in upcoming six months 4. known allergy or intolerance to hcq 5. known glucose-6 phosphate dehydrogenase deficiency 6. known eye disease associated with retinal pigmentation abnormalities 7. known diabetic retinopathy requiring past or planned laser therapy 8. inability to comply with visit schedule and protocol requirements 9. inability to manage and take medication as instructed 10. current or planned pregnancy in upcoming 12 months 11. inability or unwillingness to use reliable method of contraception (for women of childbearing years, men, or men's partners with childbearing potential), such as oral contraceptive pills, barrier method (diaphragm and condom with spermicide), intrauterine device, or depo-provera injections for 3 months prior to enrollment 12. anemia (hgb \< 9) 13. any history of bariatric (weight loss) surgery 14. current use of the medication glucophage (metformin) 15. weight changes of 6 pounds or more in the past 4 weeks 16. any other underlying or concomitant condition, which in the opinion of the principal investigator, could confound the results of the study or put the subject at undue risk

Keywords: pre-diabetes hydroxychloroquine frequently sampled intravenous glucose tolerance testing insulin resistance insulin secretion glucose tolerance
arterial waveform analysis for predicting post-induction hypotension

Conditions: Hypotension on Induction

Summary: the goal of this observational study is to develop a computation model for accurately predicting post-induction hypotension in patients receiving laparoscopic surgery under general anesthesia. the main question\[s\] it aims to answer are: • whether the corresponding characteristics on pressure wave forms could be use to predict post-induction hypotension. participants will be observed before and after induction of general anesthesia for non-invasive arterial pressure wave forms and blood pressure changes.

in this project, an equivalent circuit model will firstly be established to simulate patient's hemodynamics. this model will be applied into analyzing blood pressure wave forms in the mimic ii database. it will facilitate deep understanding of the effects of induction drugs on pressure waveforms. as a result, the corresponding characteristics on pressure wave forms will be identified. the extracted characteristics from the mimic ii database will then be applied for developing a computation model via machining learning approaches. the developed model will be validated with another available dataset of 100 patients. this project will then conduct a non-invasive and observational clinical study of 50 patients to prove the clinical value of this project. in this trial, a novel pressure sensor will be employed on patient's fingertip to continuously collect pressure waveform before and after anesthesia induction. medical records and vital signs will also be collected for exploring the potential of the developed model for predicting other events. endoscopic surgery patients will be recruited in this study.

Eligibility criteria:
inclusion criteria: * age \>= 20 years * ease of access to the hand used for the artevu device during the one-hour it is being used during the operation. * able to provide written informed consent for participation in the study. exclusion criteria: * pregnant patients. * medical or surgical condition that prevents the ability to apply the artevu device on an upper extremity finger for a period of one-hour during anesthesia and operation. * impaired skin integrity of the fingers (e.g. injuries to the finger, burn injuries, or skin graft surgery on the finger). * operations involving the upper extremities or the blood vessels of the upper extremities. * arthritis or severe deformities of the hand and fingers * prosthetic devices or jewelry (such as a wedding band) that cannot be removed from the finger to be used for the artevu device. * history of malignant hyperthermia * raynaud's disease affecting the fingers or hands. * topical allergy to abs or silicone * swelling, edema or lymphedema of the upper extremity * participants with upper extremity occlusive peripheral vascular diseases * inability of the patient to provide written informed consent.

Keywords: anesthesia induction hypotension pressure waveform machine learning
the effect of saccharomyces boulardii in clinical presentation and quality of life patient with ibs

Conditions: Irritable Bowel Syndrome

Summary: this study aims to compare the effectiveness of saccharomyces boulardii vs placebo in patient with irritable bowel syndrome

this study aims to compare the effectiveness of saccharomyces boulardii vs placebo in patient with irritable bowel syndrome within timeframe of study 28 days and then will be examined the outcome as the improvement quality of life

Eligibility criteria:
inclusion criterias: * 18 years or older * diagnosed with ibs based on rome iv criteria * agree to be participant by signing inform consent exclusion criteria: * patient who does not want to sign the inform consent
clinical trial to evaluate the efficacy and safety of suvaro®od tablet in patients with dyslipidemia

Conditions: Dyslipidemia

Summary: the aim of study is to evaluate the efficacy and safety of the new generic formulation (rosuvastatin orally disintegrating tablet (suvaro®odt) in patients with dyslipidemia.

study objectives: the aim of study is to evaluate the efficacy and safety of the new generic formulation (rosuvastatin orally disintegrating tablet (suvaro®odt) in patients with dyslipidemia. also, this study is designed to observe patients' preference and adherence for suvaro®odt. hypothesis: we hypothesized that there will be no difference in ldl-c lowering efficacy of the two formulations (suvaro®odt 10-mg or rosuvastatin immediate-release tablet (ir) 10-mg). study design: this is a randomized, multicenter, open-label, two-period crossover study with 112 enrolled patients. subjects: patients with dyslipidemia over 50 years of age who received statin treatmen for at least 2 months

Eligibility criteria:
inclusion criteria: 1. patients with dyslipidemia over 50 years of age who received statin treatmen for at least 2 months 2. written informed consent to participate in the trial exclusion criteria: 1. history of previous hypersensitivity reaction to other statins, including rosuvastatin 2. patients with acute arterial disease within 3 months 3. uncontrolled hypertensive patients defined as sbp ≥180 mm hg and dbp ≥110 mm hg, respectively 4. uncontrolled diabetes mellitus (hba1c \> 9%) 5. uncontrolled hypothyroidism defined as tsh \>1.5 within the last 6 months 6. taking other lipid lowering agent except statins 7. history of statin-induced myopathy, rhabdomyolysis 8. patients with severe hepatic or renal dysfunction 9. bmi (body mass index) \> 40 kg/m2 10. history of galactose intolerance, lapp lactose deficiency, or glucose-galactose malabsorption

Keywords: dyslipidemia orally disintegrating tablet odt rosuvastatin preference